Browse drugs

…eceived 150mg/12h, and 3% received 75mg/12h. The indication for idarucizumab use was: 56% uncontrolled bleeding, 34% emergency surgery, 7% d…

…ods A retrospective analysis included SLE patients treated with belimumab (n=25), obinutuzumab (n=8), and voclosporin (n=3) for >=6 month…

… (SGLT2i: adjusted median OR (aMOR) 1.29 (95% CI 1.23 to 1.36); GLP-1 RA: aMOR 1.48 (95% CI 1.37 to 1.62)). Treating all patients would …

…s; tofacitinib (TOF), baricitinib (BAR), upadacitinib (UPA) and filgotinib (FIL)) in patients with rheumatoid arthritis (RA) in real-world…

…5, Claude 3.7 Sonnet, Grok-2, Deepseek Cognition V2, Qwen2 72B, Gemini 2.0 Pro, Llama 3 405B and Mixtral 8×22B) on their ability to interpret …

…int difference, 95% confidence interval (CI) –26.3 to –7.1) for ivermectin versus permethrin. Secondary outcome percentage point differenc…

…ation-induced cells death.Conclusions ICT01 in combination with pembrolizumab generated clinically meaningful anti-tumor efficacy in 2L CPI-r…

…rable (figure 2). Consistent with the tumor-activated design of vilastobart, treatment was generally well-tolerated: overall (n=44), 11 pat…

…ipilimumab/chemotherapy), against KEYNOTE-189, and KEYNOTE-407 (pembrolizumab/chemotherapy). We analyzed both the progression free survival (…

… enhance tumor immunity/anti-tumor activities in animal models. HX111 could be such a candidate drug for tumor treatment, with enhanc…

…l in athymic nude mice was utilized to evaluate the efficacy of tuvusertib and N-803 combination therapy in vivo. Tuvusertib and avelumab …

…erapeutic index of ZW270 in vivo compared to wild type IL-12Fc. ZW270 was well tolerated in non-human primates (>30mg/kg) with slow e…